STING1 and non-small cell lung carcinoma: The considerable result is that STING pathway activation in NSCLC is characteristic of predictive immunotherapy response and is enhanced by cisplatin treatment, suggesting that possible predictive biomarkers and mechanisms can improve response to chemoimmunotherapy combinations [158].